REG - Haleon PLC - Evolution of operating model

HALEONAnnouncement

08/01/2026 13:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260108:nRSH2007Oa&default-theme=true

RNS Number : 2007O  Haleon PLC  08 January 2026

 

 

Haleon announces evolution of its operating model to drive growth and agility

 

08 January 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) has
today announced that it is evolving its operating model in support of its Win
as One strategy to drive its growth, productivity and culture agenda, as set
out at its Capital Markets Day in May 2025. These changes are expected to be
implemented by mid-2026.

 

Chief Growth Officer

Haleon has today created a new Chief Growth Officer (CGO) role. This role will
include broad responsibility across Haleon's existing Category, Marketing and
Strategy functions, as well as a new global Commercial Excellence team. The
CGO will lead Haleon's growth and innovation agenda in partnership with
Haleon's new Operating Units (as below) and the existing R&D and Supply
Chain functions, to better leverage Haleon's global footprint and capitalise
on the strength and breadth of its brand portfolio, in support of the
ambitions set out in May 2025.

 

Operating Units

Haleon is creating six Operating Units (OUs) to enable the Company to
capitalise on the significant growth opportunities in its key markets, with
each OU responsible for delivering business performance through the execution
of Haleon's category strategies.

 

The current EMEA & LatAm region will be separated into three constituent
OUs: Latin America (LatAm), Middle East and Africa (MEA) and Europe.
Recognising the strength of Haleon's business in India Subcontinent (ISC) and
the opportunities for growth, ISC will become its own OU, separate from Asia
Pacific. Haleon's North America OU remains unchanged.

 

Global Functions

Haleon's global functions remain responsible for setting functional priorities
in support of delivering its Win as One strategy and for driving a consistent
approach globally, making the right strategic choices to benefit the
end-to-end organisation. Haleon has appointed a new Chief Transformation
Officer (CTO), who will be responsible for coordinating and driving the
significant transformation across Haleon's business processes, operating
model, and technology changes.

 

The CGO and CTO, along with the President of each OU, will be part of Haleon's
Executive Committee and will report directly to Chief Executive Officer, Brian
McNamara. Biographies for Haleon's full Executive Team, including all newly
appointed members, can be found at www.haleon.com/who-we-are/leadership
(http://www.haleon.com/who-we-are/leadership) .

 

Brian McNamara, Chief Executive Officer of Haleon commented: "In May 2025, we
introduced our Win as One strategy, which is how we will unlock Haleon's full
potential, as we transform into a world-class consumer company. The changes
we're making to our operating model are an important part of us delivering
against our strategy to drive growth and will result in a simpler and more
agile and efficient organisation."

 

Haleon will share more detail as part of its Preliminary Full Year Results
scheduled for 25 February 2026 and will consult with employee representatives
as appropriate.

 

Enquiries

 

 Investors                                    Media

 Jo Russell              +44 7787 392441      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Victoria Durman     +44 7894 505730

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUMPGUPQGGR



            Copyright 2019 Regulatory News Service, all rights reserved